Endocrine Abstracts

Background: Patients with advanced NET have limited treatment options. In the phase III RADIANT-2 study of patients with advanced low- or intermediate-grade NET and a history of carcinoid syndrome, everolimus, an oral mTOR inhibitor, + octreotide LAR provided a clinically meaningful 5.1-month increase in median progression-free survival (PFS) compared to placebo + octreotide LAR (ESMO 2010 Abstract #LBA8). An updated safety analysis from this trial is presented.<p class="a...

Background: A recent study of a small series of patients with appendiceal neuroendocrine tumors (ANETs) fulfilling various criteria for right hemicolectomy (RHC) revealed that ≈ 25% may harbor identifiable extra-appendiceal disease. The residual disease might not have been detected using the latest European Neuroendocrine Tumors Society (ENETs) revised pathological criteria.Aims: To evaluate the latest pathological criteria for completion right hem...